Send to

Choose Destination
Zhonghua Gan Zang Bing Za Zhi. 2017 Aug 20;25(8):597-600. doi: 10.3760/cma.j.issn.1007-3418.2017.08.008.

[Clinical effect and safety of 144-week treatment with entecavir capsules in treatment-naïve HBeAg-positive patients with chronic hepatitis B].

[Article in Chinese; Abstract available in Chinese from the publisher]

Author information

The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350000, China.
The Eighth People's Hospital of Guangzhou, Guangzhou 510060, China.
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
The Second People's Hospital of Tianjin, Tianjin 300192, China.
Shanghai Public Health Clinical Center, Shanghai 201508, China.
Sichuan Provincial People's Hospital, Chengdu 610772, China.
No.81 Hospital of PLA, Nanjing 210002, China.
Jinan Infectious Disease Hospital, Jinan 250021, China.
Hainan General Hospital, Haikou 570311, China.
No.302 Hospital of PLA, Beijing 100039, China.
The Second Hospital of Nanjing, Nanjing 210003, China.
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China.


in English, Chinese

Objective: To investigate the clinical effect and safety of entecavir capsules in the treatment of treatment-naïve HBeAg-positive patients with chronic hepatitis B (CHB). Methods: A total of 158 HBeAg-positive CHB patients were given oral entecavir capsules at a dose of 0.5 mg/time once a day for 144 weeks. Clinical outcome and safety were evaluated at baseline and at 24, 48, 72, 96, 120, and 144 weeks of treatment respectively. The Fisher's exact test was used for the analysis of categorical data. Results: After 144 weeks of treatment, 90.91% of all patients achieved virologic response (< 69 IU/ml), the normalization rate of alanine aminotransferase was 88.18%, the clearance rate of HBeAg was 33.33%, and the seroconversion rate of HBeAg was 24.07%. Of all patients, 2 dropped out due to adverse events and 5 experienced serious adverse reactions. Conclusion: Entecavir capsules can inhibit viral replication and have good safety in treatment-naïve HBeAg-positive CHB patients.


Efficacy; Entecavir capsule; Safety

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Chinese Medical Association Publishing House Ltd.
Loading ...
Support Center